ProShares Ultra Nasdaq Biotechnology Rating $55.78 +0.38 (+0.69%) (As of 12/17/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrends ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.68Holdings in BIB have an aggregate rating of Moderate Buy based on 648 analyst ratings issued in the past year covering 42 companies (54.2% of the portfolio).BIB Aggregate Price Target$55.78High Prediction$55.78Average Prediction$55.78Low Prediction$55.78Holdings in BIB have an aggregate price target of $55.78 and a range of $55.78 to $55.78 covering 42 companies (54.2% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy29 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 42 BIB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.99%GILDGilead Sciences$92.80+0.8%4.5379 of 5 stars2.67$96.43 3.9%27Insider Trade5.59%VRTXVertex Pharmaceuticals$469.24+0.2%4.2033 of 5 stars2.55$505.73 7.8%31Analyst ForecastPositive News4.89%AMGNAmgen$265.95-0.2%4.596 of 5 stars2.42$319.68 20.2%26Analyst Downgrade3.94%REGNRegeneron Pharmaceuticals$740.01+2.1%4.7125 of 5 stars2.73$1,052.90 42.3%22Analyst Forecast2.89%AZNAstraZeneca$67.18+1.4%4.2246 of 5 stars2.91$89.75 33.6%11Short Interest ↓2.39%ALNYAlnylam Pharmaceuticals$246.58+1.1%4.5488 of 5 stars2.71$298.09 20.9%24Short Interest ↓1.67%BIIBBiogen$150.64+0.1%4.7464 of 5 stars2.48$245.32 62.9%29Analyst Downgrade1.63%ILMNIllumina$143.12-0.9%4.4387 of 5 stars2.70$165.95 15.9%20Short Interest ↑1.45%ARGXargenx$638.33+0.9%3.1118 of 5 stars2.91$635.11 -0.5%22Short Interest ↓Positive News1.24%MRNAModerna$40.76-2.6%4.4076 of 5 stars2.14$79.50 95.0%211.19%UTHRUnited Therapeutics$379.69+1.8%4.7153 of 5 stars2.73$370.86 -2.3%15Positive News1.10%VTRSViatris$12.59+0.5%1.4196 of 5 stars2.00$13.67 8.6%31.06%INCYIncyte$69.40-0.6%4.4809 of 5 stars2.35$76.18 9.8%20Analyst Forecast1.03%SNYSanofi$48.94+6.6%3.5438 of 5 stars3.00$57.50 17.5%3News CoverageGap UpHigh Trading Volume0.98%SMMTSummit Therapeutics$18.57-0.6%3.3841 of 5 stars2.83$33.33 79.5%60.94%INSMInsmed$73.85+0.6%3.1728 of 5 stars3.00$83.67 13.3%16Positive News0.94%NBIXNeurocrine Biosciences$136.69+2.7%4.8857 of 5 stars2.83$166.00 21.4%23Analyst ForecastPositive News0.92%BMRNBioMarin Pharmaceutical$67.19+2.5%4.9882 of 5 stars2.74$94.20 40.2%23Positive News0.89%SRPTSarepta Therapeutics$125.76-0.8%4.9058 of 5 stars2.91$178.71 42.1%22Insider TradePositive News0.87%BNTXBioNTech$117.39+2.8%2.3043 of 5 stars2.82$140.76 19.9%170.84%RPRXRoyalty Pharma$25.12+0.5%4.7144 of 5 stars2.83$41.67 65.9%60.79%MEDPMedpace$348.48-0.4%4.303 of 5 stars2.45$380.56 9.2%110.76%PCVXVaxcyte$89.86+0.4%1.7996 of 5 stars3.00$147.50 64.1%70.74%EXELExelixis$34.69-3.8%4.5642 of 5 stars2.58$31.88 -8.1%19Analyst DowngradeShort Interest ↑0.66%BGNEBeiGene$179.06+1.5%2.6334 of 5 stars2.75$253.69 41.7%80.66%ROIVRoivant Sciences$12.15+0.4%2.667 of 5 stars2.88$17.93 47.6%8Positive News0.65%ITCIIntra-Cellular Therapies$86.96+2.2%4.1678 of 5 stars2.85$97.23 11.8%130.58%RVMDRevolution Medicines$45.16+1.0%4.6632 of 5 stars3.08$63.67 41.0%12Positive News0.56%ASNDAscendis Pharma A/S$140.30+2.7%3.2153 of 5 stars2.92$191.77 36.7%13Short Interest ↑0.55%JAZZJazz Pharmaceuticals$122.49-2.2%4.8697 of 5 stars2.87$177.00 44.5%150.50%MDGLMadrigal Pharmaceuticals$306.08-1.6%4.3071 of 5 stars2.69$347.33 13.5%13Positive News0.45%HALOHalozyme Therapeutics$48.60+1.2%4.9931 of 5 stars2.60$61.11 25.7%10Positive News0.44%CYTKCytokinetics$47.78-2.5%3.9849 of 5 stars2.75$83.93 75.7%160.44%BPMCBlueprint Medicines$96.48+1.1%2.9172 of 5 stars2.71$122.11 26.6%21Insider TradeShort Interest ↑0.41%NUVLNuvalent$88.10+0.8%2.3399 of 5 stars2.85$112.60 27.8%13Positive News0.40%IONSIonis Pharmaceuticals$37.68-1.1%4.472 of 5 stars2.68$60.65 61.0%19Short Interest ↓Positive News0.39%KRYSKrystal Biotech$169.04+0.9%4.3083 of 5 stars3.00$206.67 22.3%80.39%BBIOBridgeBio Pharma$27.82+0.4%4.7325 of 5 stars2.86$47.69 71.4%14Analyst ForecastPositive News0.38%ALKSAlkermes$30.75+0.3%4.6833 of 5 stars2.58$35.42 15.2%12Positive News0.35%AXSMAxsome Therapeutics$93.51+4.3%4.7935 of 5 stars3.00$125.93 34.7%14Short Interest ↓Positive News0.34%ADMAADMA Biologics$18.63-1.8%3.8603 of 5 stars3.25$21.25 14.1%4Short Interest ↓0.34%CRNXCrinetics Pharmaceuticals$55.37+1.4%4.2142 of 5 stars2.91$70.82 27.9%11Analyst ForecastShort Interest ↓Positive News This page (NASDAQ:BIB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
